Core Viewpoint - Tempus AI's stock surged over 13%, nearing its previous high, following the announcement of FDA approval for its updated Tempus Pixel device, marking a significant regulatory milestone in the cardiac imaging field [1] Company Summary - Tempus AI's updated Tempus Pixel device received special 510(k) clearance from the FDA, allowing it to be commercially used in the United States [1] - The stock price reached $88.81 after the announcement, indicating strong market reaction and investor confidence [1]

智通财经APP获悉，周四，Tempus AI(TEM.US)大涨超13%，逼近此前新高，报88.81美元。消息面上， Tempus AI宣布，其更新版的Tempus Pixel设备获得美国食品和药物管理局(FDA)的特别510(k)许可。这 是一个重要的监管里程碑，标志着该设备在心脏成像领域的升级版正式获准在美国商业使用。 ...